Bulletin
Investor Alert

New York Markets Open in:

Sage Therapeutics Inc.

NAS: SAGE

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 30, 2022, 5:25 p.m.

/zigman2/quotes/200179567/composite

$

39.34

Change

-1.70 -4.14%

Volume

Volume 56,932

Quotes are delayed by 20 min

/zigman2/quotes/200179567/composite

Previous close

$ 38.48

$ 41.04

Change

+2.56 +6.65%

Day low

Day high

$38.59

$41.17

Open

52 week low

52 week high

$27.36

$45.74

Open

Company Description

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Do...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

395.66

Price to Book Ratio

1.45

Enterprise Value to EBITDA

-1.24

Enterprise Value to Sales

87.48

Efficiency

Total Asset Turnover

0.00

Liquidity

Current Ratio

21.14

Quick Ratio

21.14

Cash Ratio

20.45

Profitability

Gross Margin

24.94

Operating Margin

-7,306.74

Pretax Margin

-7,258.91

Net Margin

-7,258.91

Return on Assets

-22.98

Return on Equity

-24.09

Return on Total Capital

-23.96

Capital Structure

Total Debt to Total Assets

1.01

Officers and Executives

Name Age Officer Since Title
Dr. Barry E. Greene 57 2020 Director
Ms. Kimi E. Iguchi 58 2013 Chief Financial Officer
Mr. Matt Lasmanis - 2020 Chief Technology & Innovation Officer
Ms. Laura Gault - 2022 Chief Medical Officer
Dr. Albert J. Robichaud 58 2011 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/10/2022 Barry E. Greene
President and CEO; Director
14,500   Acquisition at $34.48 per share. 499,960
05/05/2022 George S. Golumbeski
Director
8,000   Acquisition at $31.45 per share. 251,600
04/27/2022 Jeffrey M. Jonas
Director
30,944   Derivative/Non-derivative trans. at $0.45 per share. 13,924
02/17/2022 Jeffrey M. Jonas
Director
4,000   Derivative/Non-derivative trans. at $0.45 per share. 1,800
02/17/2022 Kimi E. Iguchi
CFO & Treasurer
4,500   Derivative/Non-derivative trans. at $1.36 per share. 6,120
11/23/2021 Kimi E. Iguchi
CFO & Treasurer
1,000   Derivative/Non-derivative trans. at $1.36 per share. 1,360
11/22/2021 Kimi E. Iguchi
CFO & Treasurer
2,500   Derivative/Non-derivative trans. at $1.36 per share. 3,400
11/09/2021 Steven Marc Paul
Director
1   43
10/19/2021 Albert J. Robichaud
Chief Scientific Officer
1,116   Derivative/Non-derivative trans. at $40.29 per share. 44,963
10/19/2021 Jeffrey M. Jonas
Director
4,374   Derivative/Non-derivative trans. at $40.29 per share. 176,228
10/19/2021 Kimi E. Iguchi
CFO & Treasurer
1,024   Derivative/Non-derivative trans. at $40.29 per share. 41,256
10/19/2021 Stephen J. Kanes
Chief Medical Officer
1,120   Derivative/Non-derivative trans. at $40.29 per share. 45,124
10/19/2021 Anne Marie Cook
SVP, GC & Secretary
1,116   Derivative/Non-derivative trans. at $40.29 per share. 44,963
10/19/2021 Albert J. Robichaud
Chief Scientific Officer
3,800   Award at $0 per share. 0
10/19/2021 Jeffrey M. Jonas
Director
10,000   Award at $0 per share. 0
10/19/2021 Kimi E. Iguchi
CFO & Treasurer
3,800   Award at $0 per share. 0
10/19/2021 Stephen J. Kanes
Chief Medical Officer
3,800   Award at $0 per share. 0
10/19/2021 Anne Marie Cook
SVP, GC & Secretary
3,800   Award at $0 per share. 0
08/05/2021 Barry E. Greene
President and CEO; Director
23,640   Acquisition at $43.15 per share. 1,020,066
06/16/2021 Kevin Paul Starr
Director
17,842   Acquisition at $56.05 per share. 1,000,044
06/16/2021 Barry E. Greene
President and CEO; Director
8,800   Acquisition at $56.32 per share. 495,616
06/16/2021 James M. Frates
Director
1,810   Acquisition at $55.1 per share. 99,731
06/16/2021 Jeffrey M. Jonas
Director
12,000   Derivative/Non-derivative trans. at $0.45 per share. 5,400
06/16/2021 Kimi E. Iguchi
CFO & Treasurer
2,000   Derivative/Non-derivative trans. at $1.36 per share. 2,720
/news/latest/company/us/sage

MarketWatch News on SAGE

  1. Stock Futures Rise Following Tuesday Rally, Netflix Earnings

    6:13 p.m. July 19, 2022

    - Barron's Online

  2. Stock Futures Creep Higher After Release of Fed Minutes

    5:39 p.m. July 6, 2022

    - Barron's Online

  3. Sage Stock Rises on Postpartum Depression Drug Data

    8:50 a.m. June 1, 2022

    - Barron's Online

  4. Betting on Biogen Stock Isn't Worth the Risk, Analyst Says

    10:26 a.m. March 8, 2022

    - Barron's Online

  5. Sage Antidepressant Trial Hits Its Target. Why the Stock Is Down.

    9:18 a.m. Feb. 16, 2022

    - Barron's Online

  6. Big Tech Stocks Enter Correction Territory as Markets Tumble

    7:13 p.m. Oct. 4, 2021

    - Barron's Online

  7. Stocks Bounced Back Today. Strong Production Numbers Did the Trick.

    7:52 p.m. Sept. 15, 2021

    - Barron's Online

  8. Sage Therapeutics stock price target cut to $52 from $60 at Mizuho

    5:47 a.m. Aug. 4, 2021

    - Tomi Kilgore

  9. Sage Therapeutics stock price target cut to $60 from $77 at Mizuho

    5:33 a.m. June 22, 2021

    - Tomi Kilgore

  10. How Sage Therapeutics Beaten-Down Stock Could Come Back

    9:20 a.m. June 21, 2021

    - Barron's Online

  11. Biogen's FDA Win Marks a Mini-Rally in Biotech Stocks

    9:20 a.m. June 16, 2021

    - Barron's Online

  12. Sage Therapeutics price target cut to $60 from $70 at Truist Securities, stock rated hold

    7:22 a.m. June 16, 2021

    - Tonya Garcia

  13. Loading more headlines...
/news/nonmarketwatch/company/us/sage

Other News on SAGE

  1. 10-Q: SAGE THERAPEUTICS, INC.

    7:24 a.m. Nov. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. Notable earnings before Tuesday's open

    11:03 a.m. Nov. 7, 2022

    - Seeking Alpha

  3. Why Doctors Are Studying New Drugs to Treat Women’s Midlife Mood Swings

    1:34 a.m. Oct. 25, 2022

    - The Wall Street Journal Interactive Edition

  4. 10-Q: SAGE THERAPEUTICS, INC.

    6:23 a.m. Aug. 2, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. Sage Therapeutics Q2 2022 Earnings Preview

    12:09 p.m. Aug. 1, 2022

    - Seeking Alpha

  6. Notable earnings before Tuesday's open

    9:59 a.m. Aug. 1, 2022

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

SAGE Therapeutics, Inc.

215 1st Street

Cambridge, Massachusetts 02142

Phone

1 6172998380

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$6.31M

Net Income

$-457.89M

Employees

471.00

/news/pressrelease/company/us/sage

Press Releases on SAGE

  1. Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

    6:30 a.m. Nov. 9, 2022

    - BusinessWire - BZX

  2. Mental Health Claims up 75% Since 2019

    7:52 a.m. Sept. 23, 2022

    - Financial News Media

  3. Mental Health Claims up 75% Since 2019

    7:50 a.m. Sept. 23, 2022

    - PR Newswire - PRF

  4. Sage Therapeutics to Present at Upcoming August Investor Conferences

    5:30 a.m. Aug. 1, 2022

    - BusinessWire - BZX

  5. Monday 5/9 Insider Buying Report: TFC, SAGE

    11:31 a.m. May 9, 2022

    - MarketNewsVideo.com

  6. Loading more headlines...
Link to MarketWatch's Slice.